Francesco Toso

Francesco Toso

Auto-generated profile, based on publicly available information

Francesco Toso

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele; Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2023 in Dermatology Reports
Verified
Journal Article
Open access
PDF file
ACAndrea Cortese
Andrea Cortese
Luigi GargiuloLuigi Gargiulo
Luigi Gargiulo
Luciano IbbaLuciano Ibba
Luciano Ibba
GFGiovanni Fiorillo
Giovanni Fiorillo
FTFrancesco Toso
Francesco Toso
Mario ValentiMario Valenti
Mario Valenti
Genital psoriasis affects 33-63% patients with psoriasis during the course of disease, usually leading to a severe reduction of patient’s quality of life. This study aims to retrospectively asses the effectiveness of interleukin (IL)-23 and IL-17 inhibitors in a real-life population affected by moderate-to-severe plaque psoriasis with genital involvement coming from our dermatology department. A total of 86 patients with diagnosis of moderate-to-severe plaque psoriasis with severe genital involvement were enrolled. Patient characteristics, Psoriasis Area and Severity Index (PASI), and Static Physician Global Assessment of Genitalia (sPGA-G) at each visit were recorded. During the treatment, the mean PASI decreased from 12,8 at 0,63 at week 52; PGA of 0/1 was reached by 97,40% at week 52 and by 100% of patients (37/37) at week 104. No significant differences between the IL-23 and IL-17 inhibitors were observed; indeed the bio-naive group of patients demonstrated superior response compared to the group of patient bio-experienced. Our findings confirmed that IL-23 and IL-17 inhibitors as a safe and effective therapeutic option for the treatment of genital psoriasis.

29 April 2023 in Dermatology Practical & Conceptual
Verified
Journal Article
Open access
PDF file
Luigi GargiuloLuigi Gargiulo
Luigi Gargiulo
FTFrancesco Toso
Francesco Toso
Luciano IbbaLuciano Ibba
Luciano Ibba
Mario ValentiMario Valenti
Mario Valenti
ACAntonio Costanzo
Antonio Costanzo
Alessandra NarcisiAlessandra Narcisi
Alessandra Narcisi
Citation: Gargiulo L, Toso F, Ibba L, Valenti M, Costanzo A, Narcisi A. Biologics for the Treatment of Severe Acrodermatitis Continua of Hallopeau: Report of Two Cases Successfully Treated with Ixekizumab and Ustekinumab. Dermatol Pract Concept. 2023;13(2):e2023103. DOI: https://doi.org/10.5826/dpc.1302a103 Accepted: September 26, 2023; Published: April 2023 Copyright: ©2023 Gargiulo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (BY-NC-4.0), https://creativecommons.org/licenses/by-nc/4.0/, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original authors and source are credited. Funding: None. Competing interests: Antonio Costanzo has been a consultant and/or speaker for Abb-Vie, Almirall, Amgen, Janssen, Leo Pharma, Eli Lilly, Galderma, Boehringer, Novartis, Pfizer, Sandoz, and UCB. Alessandra Narcisi has been a consultant and/or speaker for Abb-Vie, Almirall, Amgen, Janssen, Leo Pharma, Eli Lilly, Boehringer, Novartis, Pfizer and UCB. Mario Valenti has been a consultant and/or speaker for, Leo Pharma, Eli Lilly, Boehringer and Sanofi. Luigi Gargiulo, Francesco Toso and Luciano Ibba have nothing to disclose. Authorship: All authors have contributed significantly to this publication. Corresponding author: Dr. Francesco Toso, MD, Dermatology Unit, Department of Biomedical Sciences IRCCS Humanitas Research Hospital, Humanitas University, Rozzano (MI), Italy. Tel: +39 0282244050 Email: francesco.toso@humanitas.it Keywords : psoriasis, acrodermatitis continua of Hallopeau, ixekizumab, ustekinumab, biologics This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

14 September 2022 in Dermatologic Therapy
Verified
Journal Article
Open access
FTFrancesco Toso
Francesco Toso
MTM. Chiara Tronconi
M. Chiara Tronconi
ACAndrea Cortese
Andrea Cortese
GFGiovanni Fiorillo
Giovanni Fiorillo
ABAlessandra Bressan
Alessandra Bressan
RBRiccardo G. Borroni
Riccardo G. Borroni

31 December 2005 in Journal of Biological Research - Bollettino della Società Italiana di Biologia Sperimentale
Verified
Journal Article
Open access
PDF file
MBMassimo Bazzocchi
Massimo Bazzocchi
EDElvira D'Amicone
Elvira D'Amicone
MDMaria Cristina Dossi
Maria Cristina Dossi
FTFrancesco Toso
Francesco Toso
LVLuigi Vigna
Luigi Vigna
PMPaolo Malvisi
Paolo Malvisi
Mummies are the most interesting discovery from ancient Egypt, and like the hieroglyphs, they have become a symbol of the civilization of the pharaohs. Interest grows even stronger when science and technology allow us to learn about what the ancient Egyptians carefully embalmed and prepared for the afterlife. For archaeologists and conservators, studying mummies is like traveling through history between the iconography of the outer container of the body to the interior of the body itself. Our research in an Egyptian mummy at the National Museum of Archaeology in Venice includes the analysis of the stucco layer of the wood sarcophagus, the masque and linen bandages, chemistry, and CT scanning. We offer data regarding materials, pigments, and the conservation of the body

29 April 2023 in Dermatology Practical & Conceptual
Verified
Journal Article
Open access
PDF file
ACAndrea Cortese
Andrea Cortese
SPSaverio Pancetti
Saverio Pancetti
TPTiziana Pressiani
Tiziana Pressiani
FTFrancesco Toso
Francesco Toso
GFGiovanni Fiorillo
Giovanni Fiorillo
RBRiccardo G. Borroni
Riccardo G. Borroni
Citation: Cortese A, Pancetti S, Pressiani T, et al. Sorafenib-Induced Acute Generalized Exanthematous Pustulosis. Dermatol Pract Concept. 2023;13(2):e2023130. DOI: https://doi.org/10.5826/dpc.1302a130 Accepted: November 17, 2022; Published: April 2023 Copyright: ©2023 Cortese et al. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (BY-NC-4.0), https://creativecommons.org/licenses/by-nc/4.0/, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original authors and source are credited. Funding: None. Competing interests: None. Authorship: All authors have contributed significantly to this publication. Corresponding author: Andrea Cortese, MD, Dermatology, Humanitas Research Hospital – IRCCS, Via A. Manzoni 56, 20089 Rozzano (MI), Italy. E-mail: andreacortese08@gmail.com Keywords : sorafenib, acute generalized exanthematous pustulosis, severe cutaneous adverse reaction, tyrosin-kinase inhibitors This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

2 November 2022 in Journal of Wound Care
Verified
Journal Article
Closed access
FTFrancesco Toso
Francesco Toso
GFGiovanni Fiorillo
Giovanni Fiorillo
ACAndrea Cortese
Andrea Cortese
Luigi GargiuloLuigi Gargiulo
Luigi Gargiulo
ACAntonio Costanzo
Antonio Costanzo
FSFederica Sanna
Federica Sanna